Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 7/20 | 0.44 |
| ▸ | MGLL | Q99685 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | AGXT | P21549 | 1/20 | 0.38 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.35 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.35 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6474641 | 0.93 | NAAA (0.40) | KIF11MGLLKDM1AERAP1IDH1 | |
| SCHEMBL6481745 | 0.93 | EPHX2 (0.41) | KIF11MGLLKDM1AIDH1CA2 | |
| SCHEMBL6481112 | 0.92 | KDM1A (0.41) | KIF11MGLLKDM1AAGXTCA2 | |
| SCHEMBL6482076 | 0.89 | KDM1A (0.38) | KDM1AERAP1CA2CYSLTR2CYSLTR1 | |
| SCHEMBL6482513 | 0.89 | CNR1 (0.39) | KIF11KDM1ACA2CYSLTR2CYSLTR1 | |
| SCHEMBL6482520 | 0.88 | KIF11 (0.46) | KIF11MGLLKDM1AAGXTERAP1 | |
| SCHEMBL6474335 | 0.88 | KDM1A (0.39) | KIF11KDM1AERAP1CA2CYSLTR2 | |
| SCHEMBL6474136 | 0.86 | NAAA (0.40) | KDM1AERAP1CA2CYSLTR2CYSLTR1 | |
| SCHEMBL6483799 | 0.84 | CA2 (0.39) | KDM1ACA2CYSLTR2CYSLTR1 | |
| SCHEMBL6474838 | 0.83 | SHMT1 (0.37) | KDM1ACA2CYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6930131-B2 | Aryl substituted 3-ethoxy phenyl trifluoromethane sulfonamides for the treatment of non-insulin dependent diabetes mellitus (NIDDM) | WYETH (US) | 2005-08-16 | — | — | US | disclosed |
| US-20030203941-A1 | Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus | WYETH (US) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203941-A1 | Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus | GPR119, INSR, SLC5A1 | KIF11 3900/4885MGLL 2631/4885KDM1A 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.